Cascade Prodrug is pursuing a strategy focused on bringing a novel hypoxia-activated chemotherapy into clinical development for treating solid tumors. The process involves candidate selection, IND-enabling studies and development of a clinical trial strategy that optimally positions liposomal CPD100 for broad therapeutic use.
To support our strategic efforts, Cascade Prodrug is keen on building relationships with partners that share in our vision. Our goal is to collaborate with investors, pharmaceutical companies, and importantly, families, who know first-hand the struggles of solid tumor cancers and chemotherapy treatments. Your investment and partnership drives our programs and will allow us to get this safer, targeted therapy in the hands of patients. Contact [email protected].com if you would like more information.